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Osteoarthritis (OA) is the most common form of degenerative arthritis, mainly characterized by the
degradation of articular cartilage and associated with subchondral bone lesions. Novel therapeutic ap-
proaches for OA include cell-based therapies that have become thriving areas of research and devel-
opment. In this context, mesenchymal stem or stromal cells (MSCs) have gained much interest based on
their trophic and immunomodulatory properties that can help tissue repair/regeneration. The present
review article discusses the interest of using MSCs in cell-therapy approaches with a focus on the
mechanisms by which MSCs might exhibit a therapeutic potential in OA. Special attention is given to the
anti-inﬂammatory function of MSCs and on miRNA modulation in OA for possible future innovative
strategies. The paper also presents the current data on the undergoing MSCs-based clinical trials in OA.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA), the most prevalent form of arthritis, affects
up to 15% of the adult population and is principally characterized by
degradation of the articular cartilage of the joint, associated with
subchondral bone lesions. Chronic, low-grade inﬂammation con-
tributes to symptoms and disease progression. Networks of diverse
innate inﬂammatory danger signals, including chemokines, cyto-
kines and alarmins are activated in OA. Besides inﬂammatory me-
diators, biomechanical injury and oxidative stress compromise the
viability of chondrocytes, leading to hypertrophic differentiation
and pro-catabolic responses with further extracellular matrix
(ECM) degradation. Better understanding the inﬂammatory path-
ophysiology should help identifying different OA subtypes in the
population and should lead to the development of new therapeutic
options.
OA is one of the most prevalent diseases of the elderly and is a
top cause of disability. There are few treatment options for OAD. No€el, Inserm U1183, CHRU
34295, France. Tel: 33-(0)-4-
ternational. Published by Elsevier Lpatients and most of them aim at reducing pain and controlling
inﬂammation to improve function. Non-steroidal anti-inﬂamma-
tory drugs (NSAIDs) and corticosteroid injections are largely used
since many years but the current treatment strategies have no
impact on the progressive degeneration of joint tissues1,2. Recent
studies suggest that disease-modifying treatments are possible.
Similar to the approach that has been successful for rheumatoid
arthritis (RA), biotherapies targeting inﬂammatory mediators such
as TNF-a, IL1 or IL6 have been tested. Although these strategies led
to a majority of disappointing results3e5, some biotherapies are still
under evaluation. As an example, we would like to point out a
recent study using adalimumb (a humanized monoclonal antibody
targeting TNFa) that reports statistically signiﬁcant less erosive
evolution on the radiological image in erosive hand OA patients
with clinical joint swelling6. The current data indeed suggest that
co-inhibition of several pro-inﬂammatory cytokines may be more
efﬁcient in OA7. In this context, mesenchymal stromal/stem cell
(MSC)-based therapy seems attractive because this innovative
therapeutic strategy could provide an enlarged anti-inﬂammatory
potential. MSCs are immunosuppressive cells, which can decrease
inﬂammation through the release of anti-inﬂammatory factors
(including IL1RA) and decrease monocyte activation. In this review,
we summarize recent data conﬁrming the role of MSCs as a po-
tential therapeutic strategy in OA.td. All rights reserved.
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Although OA has generally been proposed as a degenerative
disease, recent work suggested that low-grade inﬂammatory pro-
cesses could promote disease symptoms and accelerate disease
progression8. Some of the cartilage matrix catabolic products
probably activate macrophages and other innate immune cells to
release inﬂammatory cytokines, which in turn promote cartilage
damage progression by altering chondrocyte function9. The inter-
play between the immune system and cartilage is not well under-
stood but evidence of regulation of acute-phase response signaling
pathway, the complement pathway, and the coagulation pathway
in the joint ﬂuid of OA patients has been reported, suggesting a
contribution of inﬂammation to joint damage10.
GWAS and studies of familial clusters and twins have also shown
a relation of OA susceptibility with inﬂammation; the inﬂuence of
genetic factors being close to 70%. Studies of candidate genes and
genome analysis have identiﬁed polymorphisms or mutations in
genes involved in the synthesis of ECM or the signaling pathways of
inﬂammation. Among the identiﬁed genes are ADAMTS-12, carti-
lage intermediate layer protein (CILP), vitamin D receptor (VDR),
cyclooxygenase (COX)2, asporin (ASPN), Growth and Differentiation
Factor (GDF)5, IL4 receptor. The polymorphism rs20417 in the
promoter of the COX2 gene contributes to the genetic risk for hip
and knee OA11. However a correlation with the expression level of
PGE2 in the synovial ﬂuid has not been demonstrated.
Synovial membranes from patients with OA demonstrate low
grade synovitis compared to RA but with high expression of cyto-
kines. OA synovial tissue shows an increase in immune cell in-
ﬁltrates associated with pro-inﬂammatory cytokine expression,
including tumor necrosis factor (TNF)a, IL1b, IL6, IL8 and IL22.
Moreover, activation of the innate immune system contributes to
the persistence of OA synovial low-grade inﬂammation. Damage to
cells and cartilage ECM resulting from repeated microtrauma and
senescence generates damage-associated molecular patterns
(DAMPs) that activate the innate immune system through the toll-
like receptor (TLR) pathway12. DAMPs include fragments generated
from ECM degradation such as proteoglycans, intracellular proteins
such as heat-shock proteins or DNA. By inducing the release of
Alarmins (high mobility group box protein 1 S100A8 and S100A9)
by monocytes, they contribute to the inﬂammatory cascade. The
inﬂammatory process activates the release of enzymes by chon-
drocytes and monocytes resulting in enhanced catabolic process.
These enzymes include proteins of A Disintegrin And Metal-
loproteinase with Thrombospondin motifs (ADAMTS) family and
matrix metalloproteinases (MMP)1, 3, 13, which are directly
responsible of ECM remodeling. It has also been shown that the
joint synovial ﬂuid from OA patients contains a small number of
MSCs but their role in OA pathogenesis or cartilage regeneration
has yet to be established13. OA is therefore an inﬂammatory
musculoskeletal disease involving both innate and adaptive im-
mune response as shown by high levels of pro-inﬂammatory cy-
tokines and downstream target factors.
Characteristics and properties of mesenchymal stem cells
Mesenchymal stromal or stem cells (MSCs) can be isolated from
a variety of adult or neonatal tissues, primarily bone marrow, fat
tissue, dental pulp, placenta or umbilical cord. They are character-
ized by their ﬁbroblastic shape, their immunophenotype (CD11b,
CD14, CD34, CD45, HLA-DR, CD73þ, CD90þ, CD105þ) and their
trilineage potential of differentiation towards bone, cartilage and
adipose tissue14. Endogenous MSCs have been proposed to localize
in a perisinusoidal location in the bone marrow15 and to be marked
by nestin or leptin-receptor16,17 in mice or CD146 in humans18. Butperisinusoidal cells do not display all the properties of MSCs sug-
gesting that another skeletal stem cell should exist. Indeed, two
studies have very recently reported the identiﬁcation of endoge-
nous mouse skeletal stem cell (mSSC). The ﬁrst one identiﬁed
osteo-chondroreticular stem cells in the bone marrow on the basis
of Gremlin 1 expression while the other identiﬁed a subpopulation
of stem cells that generates two multipotent progenitor cell types
giving raise to bone, cartilage and stromal tissue19,20.
MSCs exert different functions thanks to a variety of secreted
factors. They produce growth factors, such as transforming growth
factor (TGF)b, hepatocyte growth factor (HGF), basic ﬁbroblast
growth factor (FGF) or vascular endothelial growth factor (VEGF),
that induce proliferation and angiogenesis of various cell types, in
particular ﬁbroblasts, epithelial or endothelial cells. Another
important property of MSCs is their capacity to rescue cells from
apoptosis induced by trauma, oxidative environment, radiation or
chemical injury. Some key proteins have been proposed to play
such role. Insulin growth factor (IGF)1, interleukin (IL)6 and
stanniocalcin-1 are essential for apoptotic reversal in ﬁbroblasts
while VEGF, HGF and TGFb1 have been shown to protect endo-
thelial cells from apoptosis21,22. The anti-ﬁbrotic effect of MSCs has
been largely shown in vitro and in different pre-clinical models of
ﬁbrosis (for review, see Ref. 23). Although it has been argued that
MSCsmight exert proﬁbrotic function, there is no example from the
literature that shows that MSC transplantation induces ﬁbrosis on a
developing or established disease. The protective effect of MSCs
extends beyond anti-ﬁbrosis to reduction of scar tissue formation
as exempliﬁed in a recent review of the literature24.
Finally, maybe the most studied property of MSCs is their anti-
inﬂammatory and immunosuppressive role on cells from the
adaptive and innate immune responses. MSCs interact with T cells
and inhibit the proliferation and differentiation of naïve T lym-
phocytes towards the Th1 or Th17 phenotype. We also demon-
strated that repolarization of Th17 cells depends on PD-L1
expression on MSCs25. The inhibition of differentiation of naïve T
lymphocytes was associated with an increase in the number of
functional natural Treg cells and enhanced IL-10 secretion. How-
ever, MSCs were not able to generate Treg cells when cultured with
mature Th1 or Th17 lymphocytes26. In parallel, MSCs induce a Th2-
like immune response, independently of T regulatory cell genera-
tion27. The immunomodulatory effect of MSCs is not speciﬁc, and
primary skin ﬁbroblasts are able to inhibit an inﬂammatory im-
mune response, as efﬁciently as MSCs. Similar to MSCs, skin ﬁ-
broblasts secreted nitric oxide (NO), IL6, prostaglandin (PG)E2 and
induced a Th2-like immune response28. The secretion of PGE2
induced by IL6 plays an important role in this immunomodulatory
effect27.
Both soluble and contact-dependent signals from the envi-
ronment trigger the therapeutic effect of MSCs, which in turn,
accordingly respond via the secretion of various mediators. The
soluble factors are released in the extracellular environment at the
vicinity of the cells or entrapped into extracellular vesicles (EVs),
which can transfer their content from one cell to another over long
distances and have been isolated from virtually all body ﬂuids29. In
studies on tissue regeneration, injection of MSC-derived EVs has
been shown to improve at least one major/clinical parameter
associated with organ dysfunction30. Although the effect of MSC-
derived EVs has not been addressed in rheumatic diseases, it
may be speculated that they may improve the outcomes of OA or
RA31.
The choice of MSC source for efﬁcient therapeutic effect
Since the identiﬁcation of MSCs as regulators of the immune
response in the late 1990's, the concept that MSCs are immune
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using major histocompatibility (MHC)-unmatched allogeneic cells
in several clinical applications. For osteo-articular diseases, the use
of allogeneic MSCs or MSCs from human origin was reported to be
efﬁcient in reducing the clinical signs of collagen-induced
arthritis33e35 or in improving OA in murine models without the
need of immunosuppressive drugs addition (for review, see36).
However, several preclinical and clinical studies have pointed out
that allogeneic cells may elicit a humoral and cellular immune
response in vivo and harbor the risk of inducing MHC speciﬁc
reactivity37,38. While the use of allogeneic MSCs has to face signif-
icant challenges, the therapy using autologous MSCs may raise
several difﬁculties. In addition to the expansion time required for
producing sufﬁcient quantities of cells, the variable potency of
MSCs betweenpatients and the need for suitable quantities ofMSCs
in acute conditions may limit the use of autologous MSCs in some
clinical applications39. Half of the clinical trials relied on the use of
autologous cells but the efﬁcacy of autologous over allogeneic
MSCs-based therapy still needs to be demonstrated. Because the
therapeutic effect of MSCs is proposed to be due to a hit-and-run
mechanism, the rapid elimination of allogeneic MSCs may not be
a problem, even thoughwemay assume thatMSC therapymay gain
by prolonging the persistence of the cells.
Another mean of enhancing MSC therapy could be to pre-
activate the cells before injection. Pre-activation of MSCs by in-
ﬂammatory mediators was evaluated in the murine model of acute
respiratory distress syndrome40. It resulted in higher protective
capacity which was associated with increased expression of IL10
and IL1RA (receptor antagonist), reduction of the lung injury score,
lower pulmonary edema and reduced accumulation of bron-
choalveolar lavage inﬂammatory cells and cytokines compared
with non activated cells. However contradictory results are avail-
able. MSCs pre-activation with IFN-g failed to prolong allograft
survival in a model of rat corneal allograft survival41. In rheumatic
diseases, pre-activation of MSCs with IFN-g and TNF-a failed to
ameliorate established arthritis42. The inﬂammatory environment
encountered by MSCs upon injection is likely sufﬁcient to activate
their anti-inﬂammatory function.
A better appreciation of the tissue origin of MSCs as well as the
heterogeneity of MSC subpopulations within a tissue is of impor-
tance for optimizing their therapeutic efﬁcacy for speciﬁc disease
targets. MSCs isolated from bone marrow or synovial tissue have
higher chondrogenic differentiation potential that those isolated
from other tissues while higher adipogenic activity was demon-
strated in synovium- and adipose-derived cells43. While the dif-
ferentiation potential of MSCs may vary from source to source, the
age of the donor as well as the health status may inﬂuence their
therapeutic effectiveness in certain diseases44. Indeed, MSCs from
healthy donors and OA patients present similar colony forming
unit-ﬁbroblast (CFU-F) capacity but a loss of proliferative activity
related with age45. MSCs isolated from patients with end stage OA
are functionally deﬁcient in terms of their in vitro proliferation and
differentiation potential46. These data suggest that MSCs from OA
patients have become senescent and that a correlation between the
proliferative potential and the age of nativeMSCs is suggested36. On
the other hand, speciﬁc markers for humanMSC subsets are lacking
and most of the procedures used for MSC expansion under Good
Laboratory Practices (GLP) rely on plastic adherence and give rise to
heterogeneous cell populations. There is evidence that MSCs
change their properties according to different culture conditions
and in response to different tissue environments47. Moreover,
culture-expanded MSCs have been reported to lose their trophic
function48,49. Indeed, potency assays must be established and
standardized to ensure that patients will receive functional MSCs
and comparable doses of cells.Understanding the molecular mechanisms associated with
the therapeutic effect of MSCs in OA
The interest of using MSCs in stem cell therapies for cartilage
regeneration in osteoarticular diseases has been largely dis-
cussed31,50,51. They have been used in tissue engineering ap-
proaches where they can be associated with a scaffold and
implanted in cartilage lesions. Clinical evidence supports the notion
that MSCs may be an effective treatment for traumatic injury in
chondral and osteochondral cartilage defects but few studies report
the interest of MSC-based tissue engineering approaches in OA52. In
one study focusing on patients with OA of the knee, equivalent
clinical outcomes were observed with patients receiving MSC- or
cell-free scaffolds but better arthroscopic and histological scores
were shown in the cell-transplanted group53. However, evidence
that MSCs could be better than chondrocytes is still lacking and an
easier and more direct approach could be the injection of MSCs
without scaffold36,54. Indeed, MSCs have also been evaluated as
paracrine factors-releasing cell therapy products after local or
systemic injection (for review see Ref. 31). Through the secretion of
mediators, which may stimulate endogenous regeneration and
proliferation of tissue progenitors or, counteract apoptosis or
cartilage degeneration, they may contribute to cartilage repair/
protection.
The proliferation of chondrocytes has been shown to be stim-
ulated by coculture with bone marrow- or synovium-derived
MSCs55,56. In a coculture model where human OA chondrocytes
were incubated with adipose-derived MSCs (ASCs), we were also
able to demonstrate a reduction in the expression of hypertrophic,
ﬁbrotic and inﬂammatory markers57,58. The anti-ﬁbrotic effect was
mainly attributed to the secretion of HGF by ASCs58. In this system,
ASCs alone produced very low levels of pro-inﬂammatory cytokines
and chemokines but they signiﬁcantly decreased the secretion of
IL6, IL8, monocyte chemoattractant protein (MCP)1 and macro-
phage inﬂammatory protein (MIP)1a of both chondrocytes and
synoviocytes57.
In addition to their anti-inﬂammatory potential and their ca-
pacity to stimulate endogenous cartilage regeneration, MSCs could
differentiate in vivo and replace injured cartilage59. However, few
studies have investigated the immunosuppressive potential of
differentiated MSCs towards chondrocytes60. Although one study
reported that differentiated MSCs retained their ability to suppress
allogeneic immune responses61, other reports indicated that MSC
differentiation resulted in the loss of their immunosuppressive
properties62,63. Differentiated MSCs were shown to secrete lower
levels of PGE2 and NO, two important mediators of MSC-based
immunosuppression, and to express higher levels of major histo-
compatibility component (MHC)-I, MHC-II, CD80 and CD8663.
These ﬁndings suggest that chondrogenically differentiated MSCs
not only may lose in vivo their immunosuppressive potential but
also promote the proliferation and activation of T lymphocytes. The
mechanisms by which MSCs could regenerate cartilage in OA are
not elucidated but whether their ability to differentiate into
chondrocytes may impact their capacity to inhibit inﬂammatory
responses in vivo needs further investigation.
The regenerative potential of MSCs was conﬁrmed in vivo using
experimental OA models. Intra-articular injection of murine ASCs
reduced the histological lesions of cartilage degradation in the
experimental model of collagenase-induced OA (CIOA) when
injected in a preventive protocol64. Moreover, the therapeutic effect
was signiﬁcant in this inﬂammatory CIOA model while no effect of
ASC treatment on cartilage destruction, osteophyte formation or
chondrogenesis in ligaments was found in the destabilization of
median meniscus (DMM) model65. In the CIOA model, lower levels
of S100A8, S100A9 alarmins and IL1bwere detected few hours after
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Indeed, efﬁcacy of ASC injection was observed in the model with
high activation of the synovial membrane and therefore correlated
with their anti-inﬂammatory property. In a rabbit model, Desando
et al. demonstrated that intra-articular injection of ASCs had a
structural beneﬁt. ASC treatment inhibited the progression of OA,
and was associated with a signiﬁcant decrease of Laverty's score at
16 weeks compared to the controls66. A decreased expression of
TNF-a and MMP-1 was observed in the ASC-treated groups at 16
and 24 weeks. In the low dose group (2  106 cells/joint), the
reduction of MMPs and TNF-a expression in menisci and synovial
membrane was more effective than in the high dose (6  106 cells/
joint). Several other studies reported the effect of MSCs or ASCs on
cartilage protection and OA prevention in different models of
OA67e69. Indeed, MSCs are not only involved in the maintenance of
joint homeostasis but may be of interest to restore or protect
against inﬂammation or degenerative changes associated with OA
progression.
Role of microRNAs (miRNAs) in the molecular mechanisms
sustaining MSC functions
miRNAs are small non-coding endogenous RNAs with the ca-
pacity to modulate the expression of multiple protein-encoding
genes at the posttranscriptional level. MicroRNAs control a huge
number of biologic functions such as proliferation, apoptosis or
differentiation70. In MSCs, the function of more than 60miRNAs has
been described in a recent review article71. Most of them have been
shown to be involved in differentiation and proliferation. Indeed,
global miRNA disruption through Drosha and Dicer knockdown
(both are essential component for biogenesis of miRNAs) resulted
in signiﬁcantly reduced potential of differentiation of human
MSCs72. In chondrocytes, Dicer knockdown induced a decreased
proliferation and accelerated differentiation towards a hypertro-
phic phenotype73. Several miRNAs including miR-23b, -29a, -140,
-194, -199 and -574-3p have been shown to regulate the differen-
tiation of MSCs into chondrocytes74e79. In addition, miRNAs have
been found to function in migration or apoptosis of MSCs. More
recently, the role of miRNAs in the paracrine effect of MSCs has
been exempliﬁed.
Various recent papers highlighted the importance of miRNAs in
controlling the immunosuppressive function of MSCs. As an
example, miR-27b knockdown had a positive inﬂuence on the
allosuppressive activity that inhibits T-cell proliferation via inverse
correlation of CXCL12 expression in cultured ASCs80. MiR-181a
regulated the proliferation of MSCs through TGF-b signaling
pathway and MSC immunosuppressive properties through the
MAPK signaling pathway. Speciﬁcally, miR-181a enhanced IL-6,
VEGF, and indoleamine 2,3-dioxygenase (IDO) expression, result-
ing in attenuation of the MSC immunosuppressive properties
in vitro and in vivo81. Up-regulation of miR-155 reduced the
immunosuppressive capacity of MSCs by repressing iNOS expres-
sion82. In addition, correction of the diabetic wound-healing
impairment with MSC treatment was associated with a signiﬁ-
cantly increased expression of miR-146a and related down-
regulation of its target pro-inﬂammatory genes83. Conversely,
Matysiak et al. have identiﬁed miR-146a as a negative regulator of
BM-MSC immunosuppressive function via targeting PGE2
secretion84.
Validation of new miRNAs in this process could have implica-
tions in basic science but also potentially in clinical research if the
modulation of the expression of one miRNA can enhance the
immunosuppressive effect of MSCs. Indeed, up- or down-
regulation of the expression of some miRNAs may represent a
new interesting strategy in stem cell-based therapy in OA. Over-expression of miR-140 may have a regulatory role in modulating
cartilage homeostasis and OA development through the inhibition
of several OA-related genes, such as ADAMTS585. MiR-145 is
another potential candidate because it up-regulates the expression
of genes, such as collagen II and miRNAs, such as miR-140 and miR-
655, which play important roles in cartilage86. A complementary
strategy is to use miRNAs able to inhibit or prevent OA-associated
inﬂammation. Mir-146 and miR-15a have been shown to reduce
inﬂammation and degradation initiated by IL1b and reduce syno-
vial hyperplasia in RA, respectively87,88. However, additional work
will be necessary to determine the optimal procedure to improve
stem cell technology for the treatment of OA.
Deregulation of microRNAs in OA
The altered expression of several miRNAs in OA cartilage has
initially been described in two different studies although no com-
monmiRNAwas reported89,90. Overexpression of miR-22 in normal
chondrocytes resulted in an increased expression of IL1b and
MMP13 and a decreased expression of Aggrecan. Inhibition of miR-
22 in OA chondrocytes blocked the inﬂammatory processes by
inhibiting IL1b and MMP1389. Other studies described the over-
expression of miR-146a, miR-9 and miR-34a, which regulate TNF-a
or MMP13, suggesting that they may have a protective role in
OA88,91. A more recent study has showed differential expression of
seven novel miRNAs in OA and normal chondrocytes whose func-
tion still need to be validated92.
IL1b is one of the major cytokine responsible for cartilage
degradation in OA and in a previous study, we have shown that
miR-24 is repressed in IL1b-treated chondrocytes and in cartilage of
OA patients93. MiR-146a has been proposed to negatively regulate
MMP13 although its expression gradually decreases with
advancement of the disease94. The expression of miR-146a was
inversely correlated with the expression of MMP-13 and was
strongly induced after chondrocyte stimulation with IL1b87. MiR-
146a was reported to be a negative regulator of the inﬂammatory
response and it could also be a negative regulator of MMP13 in
osteoarthritic cartilage. MiR-140 is a critical miRNA in OA as it plays
important role in chondrogenesis and cartilage development85,95.
In vivo knockout of miR-140 predisposed to age-related OA while
overexpression of miR-140 protected mice from OA through the
modulation of MMP13 and ADAMTS5 expression. More recently,
the importance of miR-125b, miR-127-5p, miR-148a and miR-21 in
OA development and progression has been described96. Finally,
Beyer and co-authors identiﬁed a signature of circulating micro-
RNAs differentially expressed in OA97. Three miRNAs, let-7e, miR-
454 and miR-885-5p were identiﬁed as predictors for severe knee
or hip OA. Let-7e was the most promising OA biomarker candidate
since it was associated with a higher susceptibility to get more than
one joint replacement surgery independently of age, sex or body
mass index.
All of these data highlight the utmost importance of miRNAs in
MSC homeostasis. Deregulation of miRNAs in OA patients seems
critical since they impact the inﬂammatory environment as well as
the functional properties of MSCs, in particular their differentiation
and immunosuppressive potential. Modulation of individual miR-
NAs in MSCs is therefore a promising strategy to enhance the
therapeutic efﬁcacy of MSCs98.
Application of MSCs to cell therapy for OA patients
Despite encouraging pre-clinical data, only few preliminary
clinical studies on the use of autologous stem cells have been
published for articular cartilage damaging diseases. Actually, the
original clinical studies focused on the use of MSCs for cartilage
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repaired to prevent subsequent OA changes. Most clinical studies
concerned knee joint injuries99e101 while one study was on ankle
cartilage defect102. Wakitani and collaborators injected autologous
BM-MSCs embedded in a collagen gel directly into the articular
cartilage defect of osteoarthritic knee joints53. Twelve patients
received autologous bonemarrow cell transplants, and twelvewere
cell-free controls. A better arthroscopic and histological score was
observed in the cell-transplanted group even though no clinical
improvement was demonstrated after 6 months. Another non-
randomized study compared 36 patients with autologous chon-
drocyte implantation and 36 patients with autologous BM-MSCs.
After 2 years, similar outcomes were obtained for the two pro-
cedures but the autologous BM-MSC-based approach was safer and
less expensive99. A recent study compared the safety of chon-
drocytes vs MSC implantation. Neither tumors nor infections were
observed on a mean 75 months of follow-up103. All these studies
generally reported presence of a hyaline-like cartilage repair tissue
within the primitive cartilage defects.
In OA, no randomized studies have been performed yet. Two
studies reporting the use of autologous BM-MSCs for treating a
small number of patients with moderate-to-severe knee OA were
recently published by Iranian groups104,105. Absence of side effects
was reported after 1-year follow-up together with an improvement
in walking time and reduction in walking pain. Moreover, MRI
displayed an increase of cartilage thickness and a decrease in the
size of subchondral edemas in half of patients105. Another non-
controlled clinical trial has shown that local injection of ASCs
improved clinical symptoms of pain and WOMAC index106 and in a
dose-escalation study, up to 100 millions of cells were well toler-
ated107. A last report on 12 patients who received 40  106 autol-
ogous BM-MSCs into the knee joint revealed improvement of
cartilagemorphology and quality usingMRI T2mapping suggesting
a possible structural beneﬁt of stem cell therapy108. Finally, our
recent results from a phase I dose escalation study on 18 patients
with knee OA showed safety of the procedure and improvement of
pain and quality of life for patients who received the lowest dose of
ASCs (2  106 cells) (Pers et al., submitted).
It might be intuitive to think that cartilage regeneration will be
especially difﬁcult to reach when the tissue is severely damaged7.
The radiographic stage that would be optimal for MSC infusion isTable I
Summary of clinical trials (on-going or completed) on stem cell therapy in OA (ClinicalT
Type of stem cells Localization Autologous or allogeneic Phase study C
ASC IA Knee Autologous I N
ASC IA Knee Autologous IeII N
ASC IA Knee Autologous IeII N
ASC þ PRP IA Knee Autologous IeII N
BMeMSC IA Knee Allogeneic IeII N
BMeMSC IA Knee Autologous IeII N
BMeMSC IA Knee Autologous II N
BMeMSC IA Knee Autologous IeII N
BMeMSC IA Knee Autologous I N
BMeMSC IA Knee Autologous IeII N
BMeMSC IA Knee Autologous IeII N
BMeMSC IA Knee Autologous II N
BMeMSC IA Knee Autologous IeII N
BMeMSC IA Knee Autologous IeII N
BMeMSC IA Knee Autologous IeII N
BMeMSC IA Hip Autologous I N
BMeMSC IA Ankle Autologous I N
BMeMSC IA Knee Allogeneic I N
UCeMSC IV or IA Knee Allogeneic IeII N
ASC: adipose-derived stem cell; BM: bone marrow; UC: umbilical cord; PRP: platelet ri
Nb: number.still not clearly deﬁned although lesions of large size (5.4 cm2)
have been associated with poor clinical and arthroscopic outcomes,
suggesting a better beneﬁt for patients with less severe OA106.
Nevertheless, Orozco et al. did not report higher beneﬁt with the
four patients with early stage OA on the 12 patients enrolled, likely
due to the small number of individuals108. All other studies
included late stage OA patients105,107; Pers et al., submitted. A
summary of on-going or completed clinical trials on stem cell
therapy in OA is given in Table I (ClinicalTrials.gov sources). All
these data support the trophic action of MSCs for reducing synovial
inﬂammation and protecting cartilage from degradation. Although
the preliminary results from these studies seem encouraging for
severe OA lesions, prospective studies should focus on OA patients
with early radiographic stage in order to prevent or limit the
structural progression of the disease. Further insight on the ther-
apeutic utility of MSCs for OA patients will come from the on-going
phase I and II trials.Conclusion
OA is a complex disease characterized by the alteration of
various molecular pathways in several compartments in the joint.
Altered pathways are likely to be different depending on OA subsets
(mechanically-induced OA, metabolic disorder associated OA, in-
ﬂammatory OA, …), joint location (knee, ankle, hip, …) or in-
dividuals. In this context, cell therapy approaches using MSCs may
be of high interest since they exert pleiotropic functions that may
give therapeutic beneﬁt on OA lesions. Preliminary results of pre-
clinical and phase I or II clinical studies using BM- or adipose
tissue-derived MSCs are promising since MSC therapy was shown
to be safe and well-tolerated. Other approaches based on the use of
embryonic stem cells (ES) or induced pluripotent stem cells (iPS)
are currently under investigation for proposing therapeutic options
or evaluating new drugs that could prevent cartilage degradation
and modify the course of OA109,110. iPS can be generated from
different tissues with signiﬁcantly less invasive procedures than
MSCs, reprogrammed towards the desired phenotype and used in
regenerative medicine111. Together with the need of controlled
long-term studies to conﬁrm whether this new strategy of MSC-
based therapy can improve pain and induce structural beneﬁt,rials.gov sources)
linicalTrials.gov identiﬁer Nb patients enrolled Status Sponsor country
CT01585857 18 C France
CT02219113 12 R Russia
CT01300598 18 C Korean
CT01739504 500 R USA
CT01586312 30 C Spain
CT01183728 12 C Spain
CT01459640 50 R Malaysia
CT02351011 12 R Canada
CT01207661 6 C Iran
CT01227694 15 C Spain
CT02123368 30 R Spain
CT01504464 40 C Iran
CT01183728 12 C Spain
CT01152125 10 R India
CT01485198 30 R Mexico
CT01499056 30 C Iran
CT01436058 6 C Iran
CT01448434 72 R Malaysia
CT02237846 40 R Panama
ch plasma; IA: intra-articular; IV: intra-venous; R: recruiting; C: completed study;
Y.-M. Pers et al. / Osteoarthritis and Cartilage 23 (2015) 2027e20352032the possibility of using other stem cell-based approaches has to be
evaluated.
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